WuXi AppTec Integrates Research, Development, and Manufacturing into Unified CRDMO Platform

The CRDMO model streamlines drug development from discovery to commercialization for biotech startups and pharma companies.

Apr. 17, 2026 at 7:37am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects representing the various stages of the drug development process, such as a beaker, a test tube, and a pill bottle, arranged elegantly on a clean, monochromatic background. The objects convey the abstract concepts of corporate strategy, finance, and risk in the pharmaceutical industry through the use of premium materials, sharp lighting, and deep shadows.WuXi AppTec's integrated CRDMO platform streamlines the complex drug development journey, from early discovery to commercial manufacturing.San Diego Today

WuXi AppTec, a global CRDMO (Contract Research, Development, and Manufacturing Organization) provider, has developed an integrated drug development model that combines research, development, and manufacturing into a single end-to-end platform. Unlike fragmented service models, the CRDMO approach supports the full lifecycle of a drug, from early discovery through preclinical development, clinical testing, and commercial manufacturing, within one continuous system. This eliminates handoffs between vendors, reduces inefficiencies, and improves consistency across stages.

Why it matters

The CRDMO model directly addresses key challenges in the life sciences industry, such as long development timelines, high costs, and low R&D success rates. By integrating research, development, and manufacturing, WuXi AppTec's platform enables faster progression from discovery to clinical and commercial stages, reduced operational complexity, better alignment of strategies, and improved visibility into timelines and resources. This benefits both biotech startups and large pharmaceutical companies seeking to accelerate drug development and expand patient access to new therapies.

The details

Unlike traditional CRO, CDMO, and CMO models that operate independently, WuXi AppTec's CRDMO model integrates all stages into a single continuous platform. This allows for seamless collaboration across scientific disciplines and operational functions, enabling drug developers to advance molecules more efficiently toward key milestones. The integrated R&D and manufacturing platform also allows early insights from research to inform downstream development and CMC (Chemistry, Manufacturing, and Controls) planning, enhancing quality and reducing risk.

  • WuXi AppTec's CRDMO model has been in development for several years, with the company continuously investing in its integrated R&D and manufacturing capabilities.

The players

WuXi AppTec

A global CRDMO (Contract Research, Development, and Manufacturing Organization) provider that has developed an integrated drug development model combining research, development, and manufacturing into a single end-to-end platform.

Got photos? Submit your photos here. ›

What’s next

WuXi AppTec plans to continue expanding its CRDMO capabilities and partnerships with biotech startups and pharmaceutical companies to accelerate drug development and improve patient access to new therapies.

The takeaway

WuXi AppTec's CRDMO model represents a significant innovation in the life sciences industry, addressing longstanding challenges around fragmentation, inefficiency, and risk in the drug development process. By integrating research, development, and manufacturing into a unified platform, the company is enabling faster, more cost-effective, and higher-quality drug development for a wide range of innovators, from small biotechs to global pharma.